These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30645824)

  • 1. bevacizumab (Avastin°) in persistent, recurrent or metastatic cervical cancer: Prolongs survival by a few months, but highly toxic.
    Prescrire Int; 2016 Oct; 25(175):233. PubMed ID: 30645824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.
    Lee N; Kim SI; Lee M; Kim HS; Kim JW; Park NH; Song YS
    In Vivo; 2019; 33(3):863-868. PubMed ID: 31028209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab in Cervical Cancer: 5 Years After.
    Pfaendler KS; Liu MC; Tewari KS
    Cancer J; 2018; 24(4):187-192. PubMed ID: 30119082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
    Raouf S; Bertelli G; Ograbek A; Field P; Tran I
    Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review.
    Willems E; Gerne L; George C; D'Hondt M
    Acta Gastroenterol Belg; 2019; 82(2):322-325. PubMed ID: 31314196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.
    Eskander RN; Tewari KS
    Future Oncol; 2015; 11(6):909-22. PubMed ID: 25760973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer.
    Xiao Y; Cheng HJ; Wang L; Luo SX
    Eur J Gynaecol Oncol; 2017; 38(1):76-79. PubMed ID: 29767869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Kurtz JE; D'Hondt V; Lécuru F; Lhommé C
    Bull Cancer; 2017 May; 104 Suppl 1():S39-S42. PubMed ID: 28625314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for the treatment of cervical cancer.
    Bizzarri N; Ghirardi V; Alessandri F; Venturini PL; Valenzano Menada M; Rundle S; Leone Roberti Maggiore U; Ferrero S
    Expert Opin Biol Ther; 2016; 16(3):407-19. PubMed ID: 26796332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
    Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
    Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.
    Alldredge JK; Tewari KS
    Oncologist; 2016 May; 21(5):576-85. PubMed ID: 27026677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer.
    Palavalli Parsons LH; Roane B; Manders DB; Richardson DL; Kehoe SM; Carlson M; Miller DS; Lea JS
    Am J Clin Oncol; 2018 Oct; 41(10):933-937. PubMed ID: 28817390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
    Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
    Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
    Zhang W; Shen Z; Luo H; Hu X; Zheng L; Zhu X
    Curr Drug Targets; 2017; 18(10):1125-1131. PubMed ID: 27138763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Krill LS; Tewari KS
    Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic therapeutic effect of low-dose bevacizumab with cisplatin-based chemotherapy for advanced or recurrent cervical cancer.
    Liu CH; Kung YH; Chien-Fu Lin J; Chuang CM; Wu HH; Jiang LY; Shih YC; Wang PH; Chen YJ
    J Chin Med Assoc; 2021 Dec; 84(12):1139-1144. PubMed ID: 34610623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of bevacizumab in the treatment of glioblastoma.
    Diaz RJ; Ali S; Qadir MG; De La Fuente MI; Ivan ME; Komotar RJ
    J Neurooncol; 2017 Jul; 133(3):455-467. PubMed ID: 28527008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastrointestinal perforation induced by bevacizumab treatment in cervix carcinoma].
    Nogué-Pujadas E; Lezcano-Rubio C; López-Sisamón D; Romeo-Marín M
    Farm Hosp; 2015 Nov; 39(6):405-6. PubMed ID: 26618385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.